An Open-Label, Prospective, Multicenter, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers

Trial Profile

An Open-Label, Prospective, Multicenter, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Human skin replacement (Primary)
  • Indications Foot ulcer
  • Focus Adverse reactions; First in man
  • Sponsors Stratatech
  • Most Recent Events

    • 17 Jan 2017 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
    • 17 Jan 2017 Planned primary completion date changed from 1 May 2018 to 1 Apr 2019.
    • 17 Jan 2017 Planned initiation date changed from 1 Apr 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top